TrumpLyftAlles | 3 points
An open label, prospective comparative study to evaluate the proposed therapy in adults with mild symptomatic COVID-19 patients receiving the standard treatment of COVID infection (India 2020-09-22) New trial on WHO portalhttps://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/09/027944
[-] TrumpLyftAlles | 1 points | Nov 06 2020 23:48:41
Montelukast 10mg/Syrup Ascoril LS 5 ml) in adults with mild symptomatic COVID-19 patients receiving the standard treatment (Tablet Cefixime 200 mg/Vitamin C, MVBC/Antacids) of COVID infection. - Add on therapy/COVID-19/2020
Not ivermectin-centric.
Interventional
Study design: Randomized, Parallel Group, Active Controlled Trial
N=30, open label, has a control arm.
Targeting sick patients:
Inclusion:
PCR+ patients
Peripheral capillary oxygen saturation (SpO2) 94% on room air at screening
Treatment:
Tab.Cefixime 200 mg
Tab.Ivermectin 12 mg
Tab.Montelukast 10 mg
Syp.Ascoril LS 5 ml: Tab.Cefixime 200 mg BD for 5 days
Tab.Ivermectin 12 mg OD for day 1
Tab.Montelukast 10 mg OD for 5 days
Syp.Ascoril LS 5 ml for 3 times a day for 5 days
I don't know how to parse the redundancies. This is what's posted on the registration. Hey, I just work here.
Control Intervention:
Tablet Cefixime 200 mg
Vitamin C, MVBC, Antacids: Tablet Cefixime 200 mg BD for 5 days
Vitamin C, MVBC, Antacids (Pantoprazole 40 mg)
Sigh.
permalink